Bones provide support and protection for organs in the body. However, over the last 15 years researchers have discovered that bones also release chemicals known as hormones, which can travel to other parts of the body and cause an effect. The cells responsible for making bone, known as osteoblasts, produce a hormone called osteocalcin which communicates with a number of different organs, including the pancreas and brain.

When osteocalcin reaches the pancreas, it promotes the release of another hormone called insulin which helps regulate the levels of sugar in the blood. Osteocalcin also travels to other organs such as muscle, where it helps to degrade fats and sugars that can be converted into energy. It also has beneficial effects on the brain, and has been shown to aid memory and reduce depression.

Osteocalcin has largely been studied in mice where levels are five to ten times higher than in humans. But it is unclear why this difference exists or how it alters the role of osteocalcin in humans. To answer this question, Al Rifai et al. used a range of experimental techniques to compare the structure and activity of osteocalcin in mice and humans.

The experiments showed that mouse osteocalcin has a group of sugars attached to its protein structure, which prevent the hormone from being degraded by an enzyme in the blood. Human osteocalcin has a slightly different protein sequence and is therefore unable to bind to this sugar group. As a result, the osteocalcin molecules in humans are less stable and cannot last as long in the blood. Al Rifai et al. showed that when human osteocalcin was modified so the sugar group could attach, the hormone was able to stick around for much longer and reach higher levels when added to blood in the laboratory.

These findings show how osteocalcin differs between human and mice. Understanding this difference is important as the effects of osteocalcin mean this hormone can be used to treat diabetes and brain disorders. Furthermore, the results reveal how the stability of osteocalcin could be improved in humans, which could potentially enhance its therapeutic effect.

Osteocalcin (OCN) is a peptide hormone secreted by osteoblasts, the bone forming cells (Lee et al., 2007). It regulates glucose metabolism by promoting beta cell proliferation and insulin secretion, and by improving insulin sensitivity (Pi et al., 2011; Ferron et al., 2012). In addition to its role in the regulation of energy metabolism, OCN is also involved in male fertility by promoting testosterone synthesis by Leydig cells (Oury et al., 2011), in muscle adaptation to exercise by improving glucose and fatty acid uptake in myocytes (Mera et al., 2016a), and in acute stress response through the inhibition of post-synaptic parasympathetic neurons (Berger et al., 2019). Overall, OCN might acts as an ‘anti-geronic’ circulating factor preventing age-related cognitive decline and muscle wasting (Khrimian et al., 2017; Mera et al., 2016b; Oury et al., 2013b). The G protein coupled receptor family C group six member A (GPRC6A) mediates OCN function in beta cells, muscles and testis (Mera et al., 2016a; Pi et al., 2011; Oury et al., 2013a), while the G protein coupled receptor 158 (Gpr158) mediates its function in the brain (Khrimian et al., 2017; Kosmidis et al., 2018).

Within the bone tissue, OCN undergoes a series of post-translational modifications (PTM) that are critical for the regulation of its endocrine functions. Prior to its secretion, in the osteoblast endoplasmic reticulum, the OCN precursor (pro-OCN) is γ-carboxylated on three glutamic acid residues (Glu) by the vitamin K-dependent γ-glutamyl carboxylase (Ferron et al., 2015). In the trans-Golgi network, pro-OCN is next cleaved by the proprotein convertase furin releasing mature carboxylated OCN (Gla-OCN) (Al Rifai et al., 2017). The presence of the negatively charged Gla residues allows Gla-OCN to bind hydroxyapatite, the mineral component of the bone extracellular matrix (ECM). It is during bone resorption that Gla-OCN is decarboxylated through a non-enzymatic process involving the acidic pH generated by the osteoclasts, ultimately leading to the release of bioactive uncarboxylated OCN (ucOCN) in the circulation (Ferron et al., 2010a; Lacombe et al., 2013). The conclusion that ucOCN represents the bioactive form of this protein in rodents is supported by cell-based assays, mouse genetics and in vivo studies [reviewed in Mera et al., 2018].

The role of OCN in the regulation of glucose metabolism appears to be conserved in humans. Human ucOCN can bind and activate human GPRC6A (De Toni et al., 2016) and promotes beta cell proliferation and insulin synthesis in human islets (Sabek et al., 2015), while mutations or polymorphisms in human GPRC6A are associated with insulin resistance (Di Nisio et al., 2017; Oury et al., 2013a). Finally, several cross-sectional and observational studies have detected a negative association between OCN or ucOCN, and insulin resistance or the risk of developing type 2 diabetes in various human populations (Lin et al., 2018; Turcotte et al., 2020; Lacombe et al., 2020).

Yet, some important species divergences exist between mice and humans with regard to OCN biology. First, only 30 out of the 46 amino acids (i.e. 65%) composing mature mouse OCN are conserved in human OCN. This is in striking contrast with other peptide hormones involved in the control of energy metabolism such as leptin and insulin whose respective sequence display about 85% conservation between mouse and human. Second, the circulating concentrations of OCN, even though decreasing with age in both species, are five to ten times higher in mice than in humans throughout life span [(Mera et al., 2016a) see also Table 1]. Based on these observations, we hypothesized that the post-translational regulation of OCN may be different between these two species, resulting in increased mouse OCN half-life in circulation.

Here, using proteomics and cell-based assays, we identified O-glycosylation as a novel PTM presents in mouse OCN, and showed that this modification increases mouse OCN half-life in plasma ex vivo and in vivo. In contrast, mature human OCN does not contain the O-glycosylation site found in the mouse protein and consequently is not normally glycosylated. Yet, a single point mutation in human OCN is sufficient to elicit its O-glycosylation and to increase its half-life in plasma.

In this study we identified O-glycosylation as a novel PTM regulating mouse ucOCN half-life in the circulation. We also showed that O-glycosylation is not found on human mature OCN, but that O-glycosylation of human OCN by means of a single amino acid change can improve its half-life in plasma ex vivo. These findings reveal an important species difference in the regulation of OCN and may also have important implication for the future use of recombinant ucOCN as a therapeutic agent in humans.

Numerous secreted proteins are subjected to mucin-type (GalNAc-type) O-glycosylation, a PTM which is initiated in the Golgi apparatus and involves multiple sequential glycosylation steps to produce diverse O-glycan structures (Steentoft et al., 2013; Bennett et al., 2012). The initiation of O-glycosylation is catalyzed by the GalNAc-Ts isoenzymes, however, the specific protein sequence(s) targeted by each of the GalNAc-Ts remain poorly characterized, although weak acceptor motifs for these have been identified by in vitro analyses (Perrine et al., 2009; Gerken et al., 2006). Here, we demonstrate that mouse OCN is O-glycosylated likely on serine 8, which is located within the amino acid sequence SVPSPDP¹¹. Interestingly, this sequence strongly matches the consensus site previously defined for GalNAc-T1 and GalNAc-T2 (Gerken et al., 2006). In particular, the presence of proline residues in position −one, +one and +three has been shown to be determinant in the recognition of peptide substrates by GalNAc-T1 and GalNAc-T2 in vitro. We used an isogenic cell library with combinatorial engineering of isoenzyme families to explore the regulation of osteocalcin O-glycosylation by GalNAc-Ts (Narimatsu et al., 2019a; Narimatsu et al., 2019b). Combined knock out of GalNAc-T1, 2 and 3 only partially abolishes mouse OCN O-glycosylation in HEK293 cells, suggesting that OCN may be a substrate for additional GalNAc-Ts.

O-glycosylation was shown to interfere with the action of proprotein convertases on several pro-hormones and receptors (Goth et al., 2015; Kato et al., 2006; May et al., 2003; Schjoldager and Clausen, 2012; Schjoldager et al., 2010; Goth et al., 2017). This appears not to be the case for OCN as its O-glycosylation does not interfere with its processing by furin in vitro and in vivo. In other proteins, such as leptin and erythropoietin, glycosylation adducts were shown to increase protein stability and half-life in circulation (Elliott et al., 2003; Creus et al., 2001). More recently, O-glycosylation was shown to protect atrial natriuretic peptide from proteolytic degradation by neprilysin or insulin-degrading enzyme in vitro (Hansen et al., 2019). Additional studies showed that sialic acid residues present in the glycosylation adducts increase protein charge, thereby improving serum half-life and decreasing liver and renal clearance (Morell et al., 1971; Runkel et al., 1998; Perlman et al., 2003; Ziltener et al., 1994). Although our data suggest that protection from proteolytic cleavage by plasmin in the plasma might be one mechanism by which O-glycosylation extend OCN half-life, we cannot exclude that in vivo, O-glycosylation may also decrease liver and renal clearance of OCN.

Mouse OCN contains arginine (R) residues at position 16 and 40, corresponding to R20 and R44 in human OCN, which could be potential cleavage sites for plasmin (Figure 5A). A putative plasmin cleavage site is present in mouse (i.e. AYK↓R⁴⁰, where the arrow indicates the cleavage site) and human (i.e. AYR↓R⁴⁴) OCN at the corresponding position (Backes et al., 2000). Bovine OCN, like the human protein, does not possess the O-glycosylation site found in mouse, and was shown to be cleaved by plasmin in vitro between R43 and R44 (Novak et al., 1997). Here we show that plasmin is sufficient to reduce the concentration non-glycosylated ucOCN, by more than 90% in two hours, confirming that mouse ucOCN is also a plasmin substrate. Supporting a role for plasmin in the cleavage of mouse OCN in vivo, OCN serum levels are decreased in mice deficient in plasmin activator inhibitor I (PAI-I), which have higher plasmin activity (Tamura et al., 2013). Interestingly, circulating plasmin activity increases with age in rats and humans (Paczek et al., 2009; Paczek et al., 2008), an observation which could in part explain the gradual reduction of serum OCN concentrations during aging (Mera et al., 2016a). Notably, a nonsynonymous rare variant (rs34702397) in OCN resulting in the conversion of R43 in a glutamine (Q) exists in humans of African ancestry and was nominally associated with insulin sensitivity index and glucose disposal in a small cohort of African Americans (Das et al., 2010). Since the R43Q variant eliminates the potential plasmin cleavage site in the C-terminal region, it will be interesting to further investigate if subjects carrying this variant have higher OCN circulating levels.

We also show that O-glycosylation protects mouse ucOCN from degradation in INS-1 cell cultures and consequently increases its biological activity. Interestingly, non-glycosylated ucOCN is stable when incubated in the INS-1 cell culture media at 37°C without cells (data not shown), suggesting that the proteolytic activity originates from the INS-1 cells and not from the culture media. The identity of a putative β-cell-derived protease responsible for ucOCN degradation remains unknown, since plasmin is expressed exclusively by the hepatocytes. Nevertheless, these results suggest that it may be more appropriate to use glycosylated ucOCN when studying the function of mouse OCN in cell culture.

We found that human OCN is not subjected to O-glycosylation and that consequently it has a reduced half-life in plasma ex vivo. The O-glycosylation sequence ‘SVPSPDP¹¹’ of mouse OCN is conserved in the human protein, except for the amino acids corresponding to S5 and S8, which are replaced by a proline (P9) and a tyrosine (Y12) (i.e. ‘PVPYPDP¹⁵’). Remarkably, we could introduce O-glycosylation into human OCN by a single amino acid change (Y12S). O-glycosylated human OCN is protected from degradation in plasma ex vivo similarly to the glycosylated mouse protein. Hence, this difference in the O-glycosylation status of OCN could potentially explain why circulating level of OCN in 1- to 6-month-old mice is 5–10 times higher than the level measured in young or adult human (Table 1).

It remains unknown if the increased half-life of O-glycosylated ucOCN will result in improved biological activity in vivo, although it was shown to be the case for other proteins (Baudys et al., 1995; Runkel et al., 1998; Elliott et al., 2003). Our cell-based assay does suggest that O-glycosylated ucOCN is active, at least on β-cells. We also showed that mouse OCN is endogenously O-glycosylated in vivo and that more than 80% of OCN, including the ucOCN fraction, is O-glycosylated in osteoblast supernatant and in serum. This suggests that the bioactive form of OCN is O-glycosylated in vivo in mice.

In summary, this work identified O-glycosylation as a previously unrecognized OCN PTM regulating its half-life in circulation in mice. This modification is not conserved in human, yet introducing O-glycosylation in human ucOCN also increases its half-life in plasma. These findings reveal an important difference between mouse and human OCN biology and also provide an approach to increase recombinant human OCN half-life in vivo, which might be relevant for the future development of OCN-based therapies for human diseases.

All the numerical data and the original western blots are available in the source data Excel file submitted with the manuscript. The raw proteomics data have been uploaded to a public server.

1. 1. Rifai OA
   2. Julien C
   3. Lacombe J
   4. Faubert D
   5. Lira-Navarrete E
   6. Narimatsu YJL
   7. Clausen H
   8. Ferron M

   (2020) figshare

   MS raw files for The half-life of the bone-derived hormone osteocalcin is regulated through O-glycosylation in mice, but not in humans.

   https://doi.org/10.6084/m9.figshare.13259891.v1

1. 1. Al Rifai O
   2. Chow J
   3. Lacombe J
   4. Julien C
   5. Faubert D
   6. Susan-Resiga D
   7. Essalmani R
   8. Creemers JW
   9. Seidah NG
   10. Ferron M

   (2017) Proprotein convertase furin regulates osteocalcin and bone endocrine function

   Journal of Clinical Investigation 127:4104–4117.

   https://doi.org/10.1172/JCI93437

   • PubMed
   • Google Scholar
2. 1. Backes BJ
   2. Harris JL
   3. Leonetti F
   4. Craik CS
   5. Ellman JA

   (2000) Synthesis of positional-scanning libraries of fluorogenic peptide substrates to define the extended substrate specificity of plasmin and thrombin

   Nature Biotechnology 18:187–193.

   https://doi.org/10.1038/72642

   • PubMed
   • Google Scholar
3. 1. Banbula A
   2. Bugno M
   3. Goldstein J
   4. Yen J
   5. Nelson D
   6. Travis J
   7. Potempa J

   (2000) Emerging family of proline-specific peptidases of Porphyromonas gingivalis: purification and characterization of serine dipeptidyl peptidase, a structural and functional homologue of mammalian prolyl dipeptidyl peptidase IV

   Infection and Immunity 68:1176–1182.

   https://doi.org/10.1128/IAI.68.3.1176-1182.2000

   • PubMed
   • Google Scholar
4. 1. Baudys M
   2. Uchio T
   3. Mix D
   4. Wilson D
   5. Kim SW

   (1995) Physical stabilization of insulin by glycosylation

   Journal of Pharmaceutical Sciences 84:28–33.

   https://doi.org/10.1002/jps.2600840108

   • PubMed
   • Google Scholar
5. 1. Bennett EP
   2. Mandel U
   3. Clausen H
   4. Gerken TA
   5. Fritz TA
   6. Tabak LA

   (2012) Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family

   Glycobiology 22:736–756.

   https://doi.org/10.1093/glycob/cwr182

   • PubMed
   • Google Scholar
6. 1. Berger JM
   2. Singh P
   3. Khrimian L
   4. Morgan DA
   5. Chowdhury S
   6. Arteaga-Solis E
   7. Horvath TL
   8. Domingos AI
   9. Marsland AL
   10. Yadav VK
   11. Rahmouni K
   12. Gao X-B
   13. Karsenty G

   (2019) Mediation of the acute stress response by the skeleton

   Cell Metabolism 30:890–902.

   https://doi.org/10.1016/j.cmet.2019.08.012

   • Google Scholar
7. 1. Bermpohl F
   2. Löster K
   3. Reutter W
   4. Baum O

   (1998) Rat dipeptidyl peptidase IV (DPP IV) exhibits endopeptidase activity with specificity for denatured fibrillar collagens

   FEBS Letters 428:152–156.

   https://doi.org/10.1016/S0014-5793(98)00515-8

   • PubMed
   • Google Scholar
8. 1. Cioffi M
   2. Molinari AM
   3. Gazzerro P
   4. Di Finizio B
   5. Fratta M
   6. Deufemia A
   7. Puca GA

   (1997) Serum osteocalcin in 1634 healthy children

   Clinical Chemistry 43:543–545.

   https://doi.org/10.1093/clinchem/43.3.543

   • PubMed
   • Google Scholar
9. 1. Coutts SJ
   2. Kelly TA
   3. Snow RJ
   4. Kennedy CA
   5. Barton RW
   6. Adams J
   7. Krolikowski DA
   8. Freeman DM
   9. Campbell SJ
   10. Ksiazek JF
   11. Bachovchin WW

   (1996) Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. variation of the P2 position of Xaa-boroPro dipeptides

   Journal of Medicinal Chemistry 39:2087–2094.

   https://doi.org/10.1021/jm950732f

   • PubMed
   • Google Scholar
10. 1. Creus S
    2. Chaia Z
    3. Pellizzari EH
    4. Cigorraga SB
    5. Ulloa-Aguirre A
    6. Campo S

    (2001) Human FSH isoforms: carbohydrate complexity as determinant of in-vitro bioactivity

    Molecular and Cellular Endocrinology 174:41–49.

    https://doi.org/10.1016/S0303-7207(00)00453-6

    • PubMed
    • Google Scholar
11. 1. Das SK
    2. Sharma NK
    3. Elbein SC

    (2010) Analysis of osteocalcin as a candidate gene for type 2 diabetes (T2D) and intermediate traits in caucasians and african americans

    Disease Markers 28:281–286.

    https://doi.org/10.1155/2010/246845

    • PubMed
    • Google Scholar
12. 1. De Toni L
    2. Guidolin D
    3. De Filippis V
    4. Tescari S
    5. Strapazzon G
    6. Santa Rocca M
    7. Ferlin A
    8. Plebani M
    9. Foresta C

    (2016) Osteocalcin and sex hormone binding globulin compete on a specific binding site of GPRC6A

    Endocrinology 157:4473–4486.

    https://doi.org/10.1210/en.2016-1312

    • PubMed
    • Google Scholar
13. 1. Di Nisio A
    2. Rocca MS
    3. Fadini GP
    4. De Toni L
    5. Marcuzzo G
    6. Marescotti MC
    7. Sanna M
    8. Plebani M
    9. Vettor R
    10. Avogaro A
    11. Foresta C

    (2017) The rs2274911 polymorphism in GPRC6A gene is associated with insulin resistance in normal weight and obese subjects

    Clinical Endocrinology 86:185–191.

    https://doi.org/10.1111/cen.13248

    • PubMed
    • Google Scholar
14. 1. Ducy P
    2. Desbois C
    3. Boyce B
    4. Pinero G
    5. Story B
    6. Dunstan C
    7. Smith E
    8. Bonadio J
    9. Goldstein S
    10. Gundberg C
    11. Bradley A
    12. Karsenty G

    (1996) Increased bone formation in osteocalcin-deficient mice

    Nature 382:448–452.

    https://doi.org/10.1038/382448a0

    • PubMed
    • Google Scholar
15. 1. Elliott S
    2. Lorenzini T
    3. Asher S
    4. Aoki K
    5. Brankow D
    6. Buck L
    7. Busse L
    8. Chang D
    9. Fuller J
    10. Grant J
    11. Hernday N
    12. Hokum M
    13. Hu S
    14. Knudten A
    15. Levin N
    16. Komorowski R
    17. Martin F
    18. Navarro R
    19. Osslund T
    20. Rogers G
    21. Rogers N
    22. Trail G
    23. Egrie J

    (2003) Enhancement of therapeutic protein in vivo activities through glycoengineering

    Nature Biotechnology 21:414–421.

    https://doi.org/10.1038/nbt799

    • PubMed
    • Google Scholar
16. 1. Ferron M
    2. Wei J
    3. Yoshizawa T
    4. Del Fattore A
    5. DePinho RA
    6. Teti A
    7. Ducy P
    8. Karsenty G

    (2010a) Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism

    Cell 142:296–308.

    https://doi.org/10.1016/j.cell.2010.06.003

    • PubMed
    • Google Scholar
17. 1. Ferron M
    2. Wei J
    3. Yoshizawa T
    4. Ducy P
    5. Karsenty G

    (2010b) An ELISA-based method to quantify osteocalcin carboxylation in mice

    Biochemical and Biophysical Research Communications 397:691–696.

    https://doi.org/10.1016/j.bbrc.2010.06.008

    • PubMed
    • Google Scholar
18. 1. Ferron M
    2. McKee MD
    3. Levine RL
    4. Ducy P
    5. Karsenty G

    (2012) Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice

    Bone 50:568–575.

    https://doi.org/10.1016/j.bone.2011.04.017

    • PubMed
    • Google Scholar
19. 1. Ferron M
    2. Lacombe J
    3. Germain A
    4. Oury F
    5. Karsenty G

    (2015) GGCX and VKORC1 inhibit osteocalcin endocrine functions

    Journal of Cell Biology 208:761–776.

    https://doi.org/10.1083/jcb.201409111

    • PubMed
    • Google Scholar
20. 1. Gerken TA
    2. Raman J
    3. Fritz TA
    4. Jamison O

    (2006) Identification of Common and Unique Peptide Substrate Preferences for the UDP-GalNAc:Polypeptide α- N -acetylgalactosaminyltransferases T1 and T2 Derived from Oriented Random Peptide Substrates

    Journal of Biological Chemistry 281:32403–32416.

    https://doi.org/10.1074/jbc.M605149200

    • Google Scholar
21. 1. Goth CK
    2. Halim A
    3. Khetarpal SA
    4. Rader DJ
    5. Clausen H
    6. Schjoldager KT

    (2015) A systematic study of modulation of ADAM-mediated ectodomain shedding by site-specific O-glycosylation

    PNAS 112:14623–14628.

    https://doi.org/10.1073/pnas.1511175112

    • PubMed
    • Google Scholar
22. 1. Goth CK
    2. Tuhkanen HE
    3. Khan H
    4. Lackman JJ
    5. Wang S
    6. Narimatsu Y
    7. Hansen LH
    8. Overall CM
    9. Clausen H
    10. Schjoldager KT
    11. Petäjä-Repo UE

    (2017)

    Site-specific O -Glycosylation by Polypeptide N -Acetylgalactosaminyltransferase 2 (GalNAc-transferase T2) Co-regulates β1 -Adrenergic Receptor N-terminal Cleavage

    Journal of Biological Chemistry 292:4714–4726.

    • Google Scholar
23. 1. Hannemann A
    2. Friedrich N
    3. Spielhagen C
    4. Rettig R
    5. Ittermann T
    6. Nauck M
    7. Wallaschofski H

    (2013) Reference intervals for serum osteocalcin concentrations in adult men and women from the study of health in pomerania

    BMC Endocrine Disorders 13:11.

    https://doi.org/10.1186/1472-6823-13-11

    • PubMed
    • Google Scholar
24. 1. Hansen LH
    2. Madsen TD
    3. Goth CK
    4. Clausen H
    5. Chen Y
    6. Dzoyashvili N
    7. Iyer SR
    8. Sangaralingham SJ
    9. Burnett JC
    10. Rehfeld JF
    11. Vakhrushev SY
    12. Schjoldager KT
    13. Goetze JP

    (2019) Correction: Discovery of O -glycans on atrial natriuretic peptide (ANP) that affect both its proteolytic degradation and potency at its cognate receptor

    Journal of Biological Chemistry 294:18516.

    https://doi.org/10.1074/jbc.AAC119.011661

    • Google Scholar
25. 1. Hohmeier HE
    2. Mulder H
    3. Chen G
    4. Henkel-Rieger R
    5. Prentki M
    6. Newgard CB

    (2000) Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion

    Diabetes 49:424–430.

    https://doi.org/10.2337/diabetes.49.3.424

    • PubMed
    • Google Scholar
26. 1. Kato K
    2. Jeanneau C
    3. Tarp MA
    4. Benet-Pagès A
    5. Lorenz-Depiereux B
    6. Bennett EP
    7. Mandel U
    8. Strom TM
    9. Clausen H

    (2006) Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis secretion of fibroblast growth factor 23 requires O-glycosylation

    The Journal of Biological Chemistry 281:18370–18377.

    https://doi.org/10.1074/jbc.M602469200

    • PubMed
    • Google Scholar
27. 1. Khrimian L
    2. Obri A
    3. Ramos-Brossier M
    4. Rousseaud A
    5. Moriceau S
    6. Nicot AS
    7. Mera P
    8. Kosmidis S
    9. Karnavas T
    10. Saudou F
    11. Gao XB
    12. Oury F
    13. Kandel E
    14. Karsenty G

    (2017) Gpr158 mediates osteocalcin's regulation of cognition

    Journal of Experimental Medicine 214:2859–2873.

    https://doi.org/10.1084/jem.20171320

    • PubMed
    • Google Scholar
28. 1. Kingsley DM
    2. Kozarsky KF
    3. Hobbie L
    4. Krieger M

    (1986) Reversible defects in O-linked glycosylation and LDL receptor expression in a UDP-Gal/UDP-GalNAc 4-epimerase deficient mutant

    Cell 44:749–759.

    https://doi.org/10.1016/0092-8674(86)90841-X

    • PubMed
    • Google Scholar
29. 1. Kosmidis S
    2. Polyzos A
    3. Harvey L
    4. Youssef M
    5. Denny CA
    6. Dranovsky A
    7. Kandel ER

    (2018) RbAp48 protein is a critical component of GPR158/OCN signaling and ameliorates Age-Related memory loss

    Cell Reports 25:959–973.

    https://doi.org/10.1016/j.celrep.2018.09.077

    • Google Scholar
30. 1. Lacombe J
    2. Karsenty G
    3. Ferron M

    (2013) In vivo analysis of the contribution of bone resorption to the control of glucose metabolism in mice

    Molecular Metabolism 2:498–504.

    https://doi.org/10.1016/j.molmet.2013.08.004

    • PubMed
    • Google Scholar
31. 1. Lacombe J
    2. Al Rifai O
    3. Loter L
    4. Moran T
    5. Turcotte AF
    6. Grenier-Larouche T
    7. Tchernof A
    8. Biertho L
    9. Carpentier AC
    10. Prud'homme D
    11. Rabasa-Lhoret R
    12. Karsenty G
    13. Gagnon C
    14. Jiang W
    15. Ferron M

    (2020) Measurement of bioactive osteocalcin in humans using a novel immunoassay reveals association with glucose metabolism and β-cell function

    American Journal of Physiology-Endocrinology and Metabolism 318:E381–E391.

    https://doi.org/10.1152/ajpendo.00321.2019

    • PubMed
    • Google Scholar
32. 1. Lee KN
    2. Jackson KW
    3. Christiansen VJ
    4. Lee CS
    5. Chun JG
    6. McKee PA

    (2006) Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein

    Blood 107:1397–1404.

    https://doi.org/10.1182/blood-2005-08-3452

    • PubMed
    • Google Scholar
33. 1. Lee NK
    2. Sowa H
    3. Hinoi E
    4. Ferron M
    5. Ahn JD
    6. Confavreux C
    7. Dacquin R
    8. Mee PJ
    9. McKee MD
    10. Jung DY
    11. Zhang Z
    12. Kim JK
    13. Mauvais-Jarvis F
    14. Ducy P
    15. Karsenty G

    (2007) Endocrine regulation of energy metabolism by the skeleton

    Cell 130:456–469.

    https://doi.org/10.1016/j.cell.2007.05.047

    • PubMed
    • Google Scholar
34. 1. Lee KN
    2. Jackson KW
    3. Christiansen VJ
    4. Dolence EK
    5. McKee PA

    (2011) Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor α2-antiplasmin

    Journal of Thrombosis and Haemostasis : JTH 9:987–996.

    https://doi.org/10.1111/j.1538-7836.2011.04195.x

    • PubMed
    • Google Scholar
35. 1. Lin X
    2. Brennan-Speranza T
    3. Levinger I
    4. Yeap B

    (2018) Undercarboxylated osteocalcin: experimental and human evidence for a role in glucose homeostasis and muscle regulation of insulin sensitivity

    Nutrients 10:847.

    https://doi.org/10.3390/nu10070847

    • Google Scholar
36. 1. Madsen TD
    2. Hansen LH
    3. Hintze J
    4. Ye Z
    5. Jebari S
    6. Andersen DB
    7. Joshi HJ
    8. Ju T
    9. Goetze JP
    10. Martin C
    11. Rosenkilde MM
    12. Holst JJ
    13. Kuhre RE
    14. Goth CK
    15. Vakhrushev SY
    16. Schjoldager KT

    (2020) An atlas of O-linked glycosylation on peptide hormones reveals diverse biological roles

    Nature Communications 11:4033.

    https://doi.org/10.1038/s41467-020-17473-1

    • PubMed
    • Google Scholar
37. 1. May P
    2. Bock HH
    3. Nimpf J
    4. Herz J

    (2003) Differential glycosylation regulates processing of lipoprotein receptors by γ-Secretase

    Journal of Biological Chemistry 278:37386–37392.

    https://doi.org/10.1074/jbc.M305858200

    • Google Scholar
38. 1. Mera P
    2. Laue K
    3. Ferron M
    4. Confavreux C
    5. Wei J
    6. Galán-Díez M
    7. Lacampagne A
    8. Mitchell SJ
    9. Mattison JA
    10. Chen Y
    11. Bacchetta J
    12. Szulc P
    13. Kitsis RN
    14. de Cabo R
    15. Friedman RA
    16. Torsitano C
    17. McGraw TE
    18. Puchowicz M
    19. Kurland I
    20. Karsenty G

    (2016a) Osteocalcin signaling in myofibers is necessary and sufficient for optimum adaptation to exercise

    Cell Metabolism 23:1078–1092.

    https://doi.org/10.1016/j.cmet.2016.05.004

    • PubMed
    • Google Scholar
39. 1. Mera P
    2. Laue K
    3. Wei J
    4. Berger JM
    5. Karsenty G

    (2016b) Osteocalcin is necessary and sufficient to maintain muscle mass in older mice

    Molecular Metabolism 5:1042–1047.

    https://doi.org/10.1016/j.molmet.2016.07.002

    • PubMed
    • Google Scholar
40. 1. Mera P
    2. Ferron M
    3. Mosialou I

    (2018) Regulation of energy metabolism by Bone-Derived hormones

    Cold Spring Harbor Perspectives in Medicine 8:a031666.

    https://doi.org/10.1101/cshperspect.a031666

    • PubMed
    • Google Scholar
41. 1. Morell AG
    2. Gregoriadis G
    3. Scheinberg IH
    4. Hickman J
    5. Ashwell G

    (1971)

    The role of sialic acid in determining the survival of glycoproteins in the circulation

    The Journal of Biological Chemistry 246:1461–1467.

    • PubMed
    • Google Scholar
42. 1. Narimatsu Y
    2. Joshi HJ
    3. Nason R
    4. Van Coillie J
    5. Karlsson R
    6. Sun L
    7. Ye Z
    8. Chen Y-H
    9. Schjoldager KT
    10. Steentoft C
    11. Furukawa S
    12. Bensing BA
    13. Sullam PM
    14. Thompson AJ
    15. Paulson JC
    16. Büll C
    17. Adema GJ
    18. Mandel U
    19. Hansen L
    20. Bennett EP
    21. Varki A
    22. Vakhrushev SY
    23. Yang Z
    24. Clausen H

    (2019a) An atlas of human glycosylation pathways enables display of the human glycome by gene engineered cells

    Molecular Cell 75:394–407.

    https://doi.org/10.1016/j.molcel.2019.05.017

    • Google Scholar
43. 1. Narimatsu Y
    2. Joshi HJ
    3. Schjoldager KT
    4. Hintze J
    5. Halim A
    6. Steentoft C
    7. Nason R
    8. Mandel U
    9. Bennett EP
    10. Clausen H
    11. Vakhrushev SY

    (2019b) Exploring regulation of protein O-Glycosylation in isogenic human HEK293 cells by differential O-Glycoproteomics

    Molecular & Cellular Proteomics 18:1396–1409.

    https://doi.org/10.1074/mcp.RA118.001121

    • PubMed
    • Google Scholar
44. 1. Novak JF
    2. Hayes JD
    3. Nishimoto SK

    (1997) Plasmin-mediated proteolysis of osteocalcin

    Journal of Bone and Mineral Research 12:1035–1042.

    https://doi.org/10.1359/jbmr.1997.12.7.1035

    • PubMed
    • Google Scholar
45. 1. Oury F
    2. Sumara G
    3. Sumara O
    4. Ferron M
    5. Chang H
    6. Smith CE
    7. Hermo L
    8. Suarez S
    9. Roth BL
    10. Ducy P
    11. Karsenty G

    (2011) Endocrine regulation of male fertility by the skeleton

    Cell 144:796–809.

    https://doi.org/10.1016/j.cell.2011.02.004

    • PubMed
    • Google Scholar
46. 1. Oury F
    2. Ferron M
    3. Huizhen W
    4. Confavreux C
    5. Xu L
    6. Lacombe J
    7. Srinivas P
    8. Chamouni A
    9. Lugani F
    10. Lejeune H
    11. Kumar TR
    12. Plotton I
    13. Karsenty G

    (2013a) Osteocalcin regulates murine and human fertility through a pancreas-bone-testis Axis

    Journal of Clinical Investigation 123:2421–2433.

    https://doi.org/10.1172/JCI65952

    • PubMed
    • Google Scholar
47. 1. Oury F
    2. Khrimian L
    3. Denny CA
    4. Gardin A
    5. Chamouni A
    6. Goeden N
    7. Huang YY
    8. Lee H
    9. Srinivas P
    10. Gao XB
    11. Suyama S
    12. Langer T
    13. Mann JJ
    14. Horvath TL
    15. Bonnin A
    16. Karsenty G

    (2013b) Maternal and offspring pools of osteocalcin influence brain development and functions

    Cell 155:228–241.

    https://doi.org/10.1016/j.cell.2013.08.042

    • PubMed
    • Google Scholar
48. 1. Paczek L
    2. Michalska W
    3. Bartlomiejczyk I

    (2008) Trypsin, elastase, plasmin and MMP-9 activity in the serum during the human ageing process

    Age and Ageing 37:318–323.

    https://doi.org/10.1093/ageing/afn039

    • PubMed
    • Google Scholar
49. 1. Paczek L
    2. Michalska W
    3. Bartlomiejczyk I

    (2009) Proteolytic enzyme activity as a result of aging

    Aging Clinical and Experimental Research 21:9–13.

    https://doi.org/10.1007/BF03324892

    • PubMed
    • Google Scholar
50. 1. Perlman S
    2. van den Hazel B
    3. Christiansen J
    4. Gram-Nielsen S
    5. Jeppesen CB
    6. Andersen KV
    7. Halkier T
    8. Okkels S
    9. Schambye HT

    (2003) Glycosylation of an N-terminal extension prolongs the half-life and increases the in vivo activity of follicle stimulating hormone

    The Journal of Clinical Endocrinology & Metabolism 88:3227–3235.

    https://doi.org/10.1210/jc.2002-021201

    • PubMed
    • Google Scholar
51. 1. Perrine CL
    2. Ganguli A
    3. Wu P
    4. Bertozzi CR
    5. Fritz TA
    6. Raman J
    7. Tabak LA
    8. Gerken TA

    (2009) Glycopeptide-preferring Polypeptide GalNAc Transferase 10 (ppGalNAc T10), Involved in Mucin-type O -Glycosylation, Has a Unique GalNAc- O -Ser/Thr-binding Site in Its Catalytic Domain Not Found in ppGalNAc T1 or T2

    Journal of Biological Chemistry 284:20387–20397.

    https://doi.org/10.1074/jbc.M109.017236

    • Google Scholar
52. 1. Pi M
    2. Wu Y
    3. Quarles LD

    (2011) GPRC6A mediates responses to osteocalcin in β-cells in vitro and pancreas in vivo

    Journal of Bone and Mineral Research 26:1680–1683.

    https://doi.org/10.1002/jbmr.390

    • PubMed
    • Google Scholar
53. 1. Pi M
    2. Kapoor K
    3. Ye R
    4. Nishimoto SK
    5. Smith JC
    6. Baudry J
    7. Quarles LD

    (2016) Evidence for osteocalcin binding and activation of GPRC6A in β-Cells

    Endocrinology 157:1866–1880.

    https://doi.org/10.1210/en.2015-2010

    • PubMed
    • Google Scholar
54. 1. Rawlings ND
    2. Morton FR
    3. Kok CY
    4. Kong J
    5. Barrett AJ

    (2008) MEROPS: the peptidase database

    Nucleic Acids Research 36:D320–D325.

    https://doi.org/10.1093/nar/gkm954

    • PubMed
    • Google Scholar
55. 1. Runkel L
    2. Meier W
    3. Pepinsky RB
    4. Karpusas M
    5. Whitty A
    6. Kimball K
    7. Brickelmaier M
    8. Muldowney C
    9. Jones W
    10. Goelz SE

    (1998) Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta)

    Pharmaceutical Research 15:641–649.

    https://doi.org/10.1023/a:1011974512425

    • PubMed
    • Google Scholar
56. 1. Saavedra YG
    2. Zhang J
    3. Seidah NG

    (2013) PCSK9 prosegment chimera as novel inhibitors of LDLR degradation

    PLOS ONE 8:e72113.

    https://doi.org/10.1371/journal.pone.0072113

    • PubMed
    • Google Scholar
57. 1. Sabek OM
    2. Nishimoto SK
    3. Fraga D
    4. Tejpal N
    5. Ricordi C
    6. Gaber AO

    (2015) Osteocalcin effect on human β-Cells mass and function

    Endocrinology 156:3137–3146.

    https://doi.org/10.1210/EN.2015-1143

    • PubMed
    • Google Scholar
58. 1. Sánchez-Garrido MA
    2. Habegger KM
    3. Clemmensen C
    4. Holleman C
    5. Müller TD
    6. Perez-Tilve D
    7. Li P
    8. Agrawal AS
    9. Finan B
    10. Drucker DJ
    11. Tschöp MH
    12. DiMarchi RD
    13. Kharitonenkov A

    (2016) Fibroblast activation protein (FAP) as a novel metabolic target

    Molecular Metabolism 5:1015–1024.

    https://doi.org/10.1016/j.molmet.2016.07.003

    • PubMed
    • Google Scholar
59. 1. Schjoldager KT
    2. Vester-Christensen MB
    3. Bennett EP
    4. Levery SB
    5. Schwientek T
    6. Yin W
    7. Blixt O
    8. Clausen H

    (2010) O-glycosylation modulates proprotein convertase activation of angiopoietin-like protein 3: possible role of polypeptide GalNAc-transferase-2 in regulation of concentrations of plasma lipids

    The Journal of Biological Chemistry 285:36293–36303.

    https://doi.org/10.1074/jbc.M110.156950

    • PubMed
    • Google Scholar
60. 1. Schjoldager KT
    2. Vakhrushev SY
    3. Kong Y
    4. Steentoft C
    5. Nudelman AS
    6. Pedersen NB
    7. Wandall HH
    8. Mandel U
    9. Bennett EP
    10. Levery SB
    11. Clausen H

    (2012) Probing isoform-specific functions of polypeptide GalNAc-transferases using zinc finger nuclease glycoengineered SimpleCells

    PNAS 109:9893–9898.

    https://doi.org/10.1073/pnas.1203563109

    • PubMed
    • Google Scholar
61. 1. Schjoldager K
    2. Clausen H

    (2012) Site-specific protein O-glycosylation modulates proprotein processing — Deciphering specific functions of the large polypeptide GalNAc-transferase gene family

    Biochimica Et Biophysica Acta (BBA) - General Subjects 1820:2079–2094.

    https://doi.org/10.1016/j.bbagen.2012.09.014

    • Google Scholar
62. 1. Steentoft C
    2. Vakhrushev SY
    3. Vester-Christensen MB
    4. Schjoldager KT
    5. Kong Y
    6. Bennett EP
    7. Mandel U
    8. Wandall H
    9. Levery SB
    10. Clausen H

    (2011) Mining the O-glycoproteome using zinc-finger nuclease-glycoengineered SimpleCell lines

    Nature Methods 8:977–982.

    https://doi.org/10.1038/nmeth.1731

    • PubMed
    • Google Scholar
63. 1. Steentoft C
    2. Vakhrushev SY
    3. Joshi HJ
    4. Kong Y
    5. Vester-Christensen MB
    6. Schjoldager KT
    7. Lavrsen K
    8. Dabelsteen S
    9. Pedersen NB
    10. Marcos-Silva L
    11. Gupta R
    12. Bennett EP
    13. Mandel U
    14. Brunak S
    15. Wandall HH
    16. Levery SB
    17. Clausen H

    (2013) Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology

    The EMBO Journal 32:1478–1488.

    https://doi.org/10.1038/emboj.2013.79

    • PubMed
    • Google Scholar
64. 1. Tamura Y
    2. Kawao N
    3. Okada K
    4. Yano M
    5. Okumoto K
    6. Matsuo O
    7. Kaji H

    (2013) Plasminogen activator inhibitor-1 is involved in streptozotocin-induced bone loss in female mice

    Diabetes 62:3170–3179.

    https://doi.org/10.2337/db12-1552

    • PubMed
    • Google Scholar
65. 1. Turcotte AF
    2. Grenier-Larouche T
    3. Lacombe J
    4. Carreau AM
    5. Carpentier AC
    6. Mac-Way F
    7. Tchernof A
    8. Richard D
    9. Biertho L
    10. Lebel S
    11. Marceau S
    12. Ferron M
    13. Gagnon C

    (2020) Association between changes in bioactive osteocalcin and glucose homeostasis after biliopancreatic diversion

    Endocrine 69:526–535.

    https://doi.org/10.1007/s12020-020-02340-2

    • PubMed
    • Google Scholar
66. 1. Ziltener HJ
    2. Clark-Lewis I
    3. Jones AT
    4. Dy M

    (1994)

    Carbohydrate does not modulate the in vivo effects of injected interleukin-3

    Experimental Hematology 22:1070–1075.

    • PubMed
    • Google Scholar

Author details

1. Omar Al Rifai

   1. Molecular Physiology Research unit, Institut de Recherches Cliniques de Montréal, Montréal, Canada
   2. Programme de biologie moléculaire, Université de Montréal, Montréal, Canada

   Contribution

   Conceptualization, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft

   Competing interests

   No competing interests declared

2. Catherine Julien

   Molecular Physiology Research unit, Institut de Recherches Cliniques de Montréal, Montréal, Canada

   Contribution

   Investigation, Methodology, Writing - review and editing

   Competing interests

   No competing interests declared

3. Julie Lacombe

   Molecular Physiology Research unit, Institut de Recherches Cliniques de Montréal, Montréal, Canada

   Contribution

   Conceptualization, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing - review and editing

   Competing interests

   No competing interests declared

4. Denis Faubert

   Proteomics Discovery Platform, Institut de Recherches Cliniques de Montréal, Montréal, Canada

   Contribution

   Resources, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - review and editing

   Competing interests

   No competing interests declared

5. Erandi Lira-Navarrete

   University of Copenhagen, Faculty of Health Sciences, Copenhagen Center for Glycomics, Departments of Cellular and Molecular Medicine, Copenhagen, Denmark

   Contribution

   Investigation

   Competing interests

   No competing interests declared

6. Yoshiki Narimatsu

   University of Copenhagen, Faculty of Health Sciences, Copenhagen Center for Glycomics, Departments of Cellular and Molecular Medicine, Copenhagen, Denmark

   Contribution

   Investigation, Visualization, Writing - review and editing

   Competing interests

   No competing interests declared

7. Henrik Clausen

   University of Copenhagen, Faculty of Health Sciences, Copenhagen Center for Glycomics, Departments of Cellular and Molecular Medicine, Copenhagen, Denmark

   Contribution

   Resources, Supervision, Writing - review and editing

   Competing interests

   No competing interests declared

8. Mathieu Ferron

   1. Molecular Physiology Research unit, Institut de Recherches Cliniques de Montréal, Montréal, Canada
   2. Programme de biologie moléculaire, Université de Montréal, Montréal, Canada
   3. Département de Médecine, Université de Montréal, Montréal, Canada
   4. Division of Experimental Medicine, McGill University, Montréal, Canada

   Contribution

   Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Writing - original draft, Project administration, Writing - review and editing

   For correspondence

   mathieu.ferron@ircm.qc.ca

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-5858-2686

• 2,210

  views

• 246

  downloads

• 9

  citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.